期刊
CANCER BIOLOGY & THERAPY
卷 22, 期 3, 页码 225-237出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/15384047.2021.1883185
关键词
Polyamines; difluoromethylornithine; transport inhibitor; braf inhibition; cxcr4
类别
资金
- Department of Defense Congressionally Directed Medical Research Program [W81XWH-16-1-037]
- National Cancer Institute [CA190952]
BRAF inhibitors are effective in treating melanoma but recurrences are common. A novel compound, AP, has shown promise in delaying recurrence and reducing tumor-promoting macrophages in BRAF inhibitor-resistant melanoma. AP targets polyamine transport system in BRAF inhibitor-resistant CSCs and blocks CXCR4 signaling in invasive melanoma cells and pro-tumorigenic macrophages.
BRAF mutations are present in over half of all melanoma tumors. Although BRAF inhibitors significantly improve survival of patients with metastatic melanoma, recurrences occur within several months. We previously reported that BRAF mutant melanoma cells are more sensitive to a novel arylmethyl-polyamine ( AP ) compound that exploits their increased polyamine uptake compared to that of BRAF wildtype cells. Using an animal model of BRAF inhibitor-resistant melanoma, we show that co-treatment with the BRAF inhibitor, PLX4720, and AP significantly delays the recurrence of PLX4720-resistant melanoma tumors and decreases tumor-promoting macrophages. Development of BRAF inhibitor-resistance enriches for metastatic cancer stem cells (CSC) and increases tumor-promoting macrophages. In vitro studies demonstrated that CD304(+), CXCR4(+) spheroid cultures of BRAF mutant melanoma cells are resistant to PLX4720 but are more sensitive to AP compared to monolayer cultures of the same cells. AP significantly inhibited YUMM1.7 melanoma cell invasiveness across a Matrigel-coated filter using the CXCR4 ligand, SDF-1 alpha, as the chemoattractant. AP also blocked the chemotactic effect of SDF-1 alpha on CXCR4(+) macrophages and inhibited M2 polarization of macrophages. In melanoma-macrophage co-cultures, AP prevented the PLX4720-induced release of pro-tumorigenic growth factors, such as VEGF, from macrophages and prevented the macrophage rescue of BRAF mutant melanoma cells treated with PLX4720. Our study offers a novel therapy ( AP ) to treat chemo-resistant melanoma. AP is unique because it targets the polyamine transport system in BRAF inhibitor-resistant CSCs and also blocks CXCR4 signaling in invasive melanoma cells and pro-tumorigenic macrophages.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据